{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:28:55Z","timestamp":1772782135188,"version":"3.50.1"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Oncology clinical trials terms and definitions have become increasingly complex, which has led to shortcomings among research staff and healthcare providers in informing clinical trial participants with the study results and consenting procedures in simple language. Understanding oncology clinical trial terms is of critical importance to assist patients and caregivers in making cancer treatment decisions, including enrollment into clinical trials. The U.S. Food and Drug Administration\u2019s (FDA) Oncology Center of Excellence (OCE) organized a physician and patient advocate-led focus group, with the primary goal of publishing a patient-centric public glossary of select cancer clinical trial terms for healthcare providers, patients, and caregivers. This commentary reports the results of the focus group sessions that gave FDA OCE valuable insights into how patients perceive clinical trial terms and how oncology clinical trial definitions can be improved to effectively communicate information to the patients to make better informed decisions about their treatment options.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad034","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:19:03Z","timestamp":1678234743000},"page":"379-382","source":"Crossref","is-referenced-by-count":4,"title":["The Development of the Oncology Center of Excellence Patient-Friendly Language Glossary of Oncology Clinical Trial Terms"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-9680","authenticated-orcid":false,"given":"Danielle","family":"Krol","sequence":"first","affiliation":[{"name":"Oncology Center of Excellence, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Kim","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Gao","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laleh","family":"Amiri-Kordestani","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia A","family":"Beaver","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kluetz","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"issue":"16","key":"2023050815245680000_CIT0001","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2007.14.8114","article-title":"Influence of clinical communication on patients\u2019 decision making on participation in clinical trials","volume":"26","author":"Albrecht","year":"2008","journal-title":"J Clin Oncol."},{"issue":"8","key":"2023050815245680000_CIT0002","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1634\/theoncologist.2018-0761","article-title":"Patient-Friendly Language to Facilitate Treatment Choice for Patients with Cancer","volume":"24","author":"Kim","year":"2019","journal-title":"Oncologist."},{"issue":"2","key":"2023050815245680000_CIT0003","doi-asserted-by":"crossref","first-page":"e0172957","DOI":"10.1371\/journal.pone.0172957","article-title":"Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study","volume":"12","author":"Schumacher","year":"2017","journal-title":"PLoS One"},{"key":"2023050815245680000_CIT0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41241-018-0065-9","article-title":"Language as a barrier to cancer clinical trial accrual: assessing consenting team knowledge and practices for cancer clinical trial consent among low English fluency patients.","volume":"38","author":"Staples","year":"2018","journal-title":"Appl Cancer Res."},{"issue":"4","key":"2023050815245680000_CIT0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s13187-016-0994-5","article-title":"Evaluating the Use of Plain Language in a Cancer Clinical Trial Website\/App","volume":"32","author":"Schultz","year":"2017","journal-title":"J Cancer Educ."},{"issue":"12","key":"2023050815245680000_CIT0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2020-0402","article-title":"Patients\u2019 Understanding of Oncology Clinical Endpoints: Environmental Scan and Focus Groups","volume":"25","author":"Sullivan","year":"2020","journal-title":"Oncologist"},{"key":"2023050815245680000_CIT0007","author":"Patient-Friendly Language for Cancer Clinical Trials, FDA Oncology Center of Excellence website","year":"2021"},{"key":"2023050815245680000_CIT0008","author":"Partners in Progress Public Workshop","year":"2018"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/379\/50247566\/oyad034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/379\/50247566\/oyad034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T16:27:27Z","timestamp":1683563247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/5\/379\/7071727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":8,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,7]]},"published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad034","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,3,7]]}}}